Marinomed Biotech AG and the 15th International Investment Forum

Marinomed Biotech AG, a biopharmaceutical company specializing in immunological and antiviral treatments, is set to participate in the 15th International Investment Forum (IIF) scheduled for May 21, 2025. The event, organized by GBC AG and Apaton Finance GmbH, will be held online and promises to provide direct access to listed companies from Europe, North America, and Australia. Marinomed Biotech, listed on the Vienna Stock Exchange, will have the opportunity to showcase its innovative therapies and engage with potential investors.

Company Overview

Marinomed Biotech AG operates in the health care sector, focusing on the development of therapies based on patent-protected technology platforms. The company serves patients primarily in Austria, with its main operations based in Vienna. As of May 8, 2025, Marinomed Biotech’s close price was EUR 12.25, with a 52-week high of EUR 17.9 and a low of EUR 2. The company’s market capitalization stands at EUR 21,695,625.

Market Context

The Vienna Stock Exchange has shown positive momentum recently, with the ATX Prime index opening the week on May 12, 2025, at 2,211.77 points, marking a 1.87% increase. This positive trend is part of a broader upward movement observed since the beginning of the year, with the ATX Prime gaining 3.94% over the past week alone.

Event Details

The 15th International Investment Forum will feature companies from forward-looking sectors, including medical technology and biotechnology. Marinomed Biotech AG will join other industry leaders in presenting their advancements and strategic directions. The event will commence at 9:55 a.m. CEST and is expected to attract significant attention from investors and industry stakeholders.

For more information about Marinomed Biotech AG and its participation in the IIF, interested parties can visit the company’s website at www.marinomed.com .